Cetera Investment Advisers’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Cetera Investment Advisers’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,588	Closed	-$408K	–	2271
2022 Q4	$408K	Buy	+3,588	New	+$298K	﹤0.01%	1485
2022 Q3	–	Sell	-2,578	Closed	-$206K	–	1904
2022 Q2	$206K	Sell	2,578 -296	-10%	-$28K	﹤0.01%	1641
2022 Q1	$302K	Buy	2,874 +267	+10%	+$26K	﹤0.01%	1473
2021 Q4	$281K	Buy	2,607 +392	+18%	+$42.8K	﹤0.01%	1527
2021 Q3	$243K	Sell	2,215 -128	-5%	-$13.3K	﹤0.01%	1566
2021 Q2	$219K	Buy	+2,343	New	+$216K	﹤0.01%	1620

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cetera Investment Advisers's HZNP Position: Q1 2023 in Review

Cetera Investment Advisers sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 3,588 shares — an estimated $408K sold.

Cetera Investment Advisers first reported a position in HZNP in Q2 2021 and held it in 6 quarters. The position peaked at $408K in Q4 2022. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Cetera Investment Advisers reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Cetera Investment Advisers sold 3,588 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $408K.
Cetera Investment Advisers first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2021 and held it in 6 quarters.
Cetera Investment Advisers's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $408K in Q4 2022.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Cetera Investment Advisers's 13F filing for Q1 2023, filed 15 May 2023.